A One Nucleus and Lonza symposium
Digitally delivered | Monday 29 March 2021
Gain insight and discuss the challenges of early stage biopharmaceutical development
One Nucleus and Lonza Biologics are pleased to invite you to join us for a complimentary virtual symposium to gain insight from experts in the different approaches and techniques to successfully progress biotherapeutic candidates from discovery to the clinic. Enjoy updates on enhancements to new and established technologies enabling translational research. The day includes talks from industry experts, local companies and technical specialists from Lonza.
Our networking breaks and virtual lunch offers the opportunity to speak with fellow scientists, presenters and Lonza specialists. In the days following the symposium, you will have the opportunity to book a virtual consultancy session with one of Lonza’s technical experts.
Register Here
Agenda (U.K. Time)
08.30 – 08.45 |
Welcome and symposium overview |
08.45 – 09.25 |
Keynote Presentation |
09.25 – 09:50 | Right first time: optimize and de-risk your early development journey Dr. Yvette Stallwood | Head of Applied Protein Services, Lonza |
09:50 – 10.15 | Bispecific Discovery: Where do we start and where are we going? Dr. Ed McGowan, Director of Antibody Discovery & Development, Isogenica |
10.15 – 10.30 |
VIRTUAL COFFEE BREAK | NETWORK TABLES WITH SPEAKERS |
10.30 – 11.10 | Approaches to maximize successful development of cell lines expressing a diverse range of proteins Dr. Alison Porter | Head of Expression System Sciences, Lonza |
11.10 – 11:35 | The CB307 Humabody journey: From Molecule to Medicine Dr. Julia Pizzey | Director CMC Analytical Development, Crescendo Biologics |
11:35 – 12.00 | A step forward – combined strategies to enhance the performance of Pichia pastoris for the development of novel biotherapeutics Dr. Joachim Klein | Head of Strain Development and Cell Banking, Microbial Development Services, Lonza |
12.00 – 12.40 | VIRTUAL NETWORKING LUNCH | NETWORKING TABLES WITH SPEAKERS |
12.40 – 13.00 |
AI-Augmented Drug Discovery |
13.00 – 13.20 |
Unlocking the next generation of antibody drug conjugate cancer therapeutics |
13:20 – 13:40 |
KnotBody technology: Antibody-like modulators of ion channels by fusing venom-derived peptides into antibody CDR loops |
13:45 – 13:50 |
WRAP UP AND END OF SYMPOSIUM |